Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
Public ClinicalTrials.gov record NCT00157053. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of Pharmacokinetics, Safety, Efficacy and Immunogenicity of rAHF-PFM in Previously Treated Hemophilia A Patients - A Continuation Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A subjects. The study consists of 2 parts: Part 1 is a pharmacokinetic and safety study, and Part 2 is an evaluation of efficacy and safety. The study is open to patients who completed Baxter Study 069901.
Study identification
- NCT ID
- NCT00157053
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 10 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2001
- Primary completion
- Aug 2, 2004
- Completion
- Aug 2, 2004
- Last update posted
- Aug 23, 2021
2001 – 2004
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mountain States Regional Hemophilia and Thrombosis Center | Aurora | Colorado | 80045 | — |
| Childrens Healthcare of Atlanta Blood Bank | Atlanta | Georgia | 30322 | — |
| Comprehensive Bleeding Disorders Center | Peoria | Illinois | 61614 | — |
| Indiana Hemophilia & Thrombosis Center | Indianapolis | Indiana | 46260 | — |
| Michigan State University | East Lansing | Michigan | 48824 | — |
| University of Medicine & Dentistry of New Jersey | New Brunswick | New Jersey | 08903-0019 | — |
| Cornell Medical Center | New York | New York | 10021 | — |
| Mt. Sinai Medical School | New York | New York | 10029 | — |
| Children's Hospital Medical Center Pharmacy | Cincinnati | Ohio | 45229 | — |
| Hemophilia Center of Western Pennsylvania | Pittsburgh | Pennsylvania | 15213-4306 | — |
| Puget Sound Blood Center | Seattle | Washington | 98104-1256 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00157053, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2021 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00157053 live on ClinicalTrials.gov.